1.广西中医药大学研究生院(广西 南宁 530001)
2.广西中医药大学第一附属医院老年病科(广西 南宁 530023)
黄少东,男,硕士研究生,住院医师,主要从事中医药防治帕金森病、脑血管病的临床研究工作
梁健芬,主任医师,硕士研究生导师;E-mail:ljy-3827@163.com
扫 描 看 全 文
黄少东, 梁健芬, 张兴博, 等. 加味五虎追风散对肾虚血瘀型帕金森病非运动症状影响的临床研究[J]. 上海中医药杂志, 2021,55(5):50-53,62.
Shaodong HUANG, Jianfen LIANG, Xingbo ZHANG, et al. Clinical study on effect of modified Wuhu Zhuifeng Powder on non-motor symptoms of Parkinson’s disease patients with kidney deficiency and blood stasis syndrome[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(5):50-53,62.
黄少东, 梁健芬, 张兴博, 等. 加味五虎追风散对肾虚血瘀型帕金森病非运动症状影响的临床研究[J]. 上海中医药杂志, 2021,55(5):50-53,62. DOI: 10.16305/j.1007-1334.2021.1908122.
Shaodong HUANG, Jianfen LIANG, Xingbo ZHANG, et al. Clinical study on effect of modified Wuhu Zhuifeng Powder on non-motor symptoms of Parkinson’s disease patients with kidney deficiency and blood stasis syndrome[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(5):50-53,62. DOI: 10.16305/j.1007-1334.2021.1908122.
目的,2,观察加味五虎追风散治疗肾虚血瘀型帕金森病非运动症状的临床疗效。,方法,2,将84例肾虚血瘀型帕金森病患者随机分为对照组和治疗组,每组42例。对照组予多巴丝肼片治疗,治疗组在对照组治疗基础上加服加味五虎追风散。两组疗程均为3个月,观察临床疗效及用药安全性,比较帕金森病非运动症状问卷(NMS-Quest)、汉密尔顿抑郁量表(HAMD)、帕金森病睡眠量表(PDSS)、简明精神状态量表(MMSE)评分以及血清脂联素(APN)、尿酸(UA)水平的变化情况。,结果,2,①试验期间,两组均未出现脱落病例,最终完成试验者84例。②治疗组、对照组总有效率分别为83.33%、26.19%;组间临床疗效比较,差异有统计学意义(,P,<,0.05)。③治疗前后组内比较,两组NMS-Quest、HAMD评分均差异有统计学意义(,P,<,0.05),但治疗组明显降低,对照组明显升高;组间治疗后比较,治疗组NMS-Quest、HAMD评分明显低于对照组(,P,<,0.05)。④治疗前后组内比较,治疗组PDSS、MMSE评分差异有统计学意义(,P,<,0.05),而对照组差异无统计学意义(,P,>,0.05);组间治疗后比较,治疗组PDSS、MMSE评分明显高于对照组(,P,<,0.05)。⑤治疗前后组内比较,治疗组APN、UA水平差异有统计学意义(,P,<,0.05),而对照组差异无统计学意义(,P,>,0.05);组间治疗后比较,治疗组APN、UA水平明显高于对照组(,P,<,0.05)。⑥两组不良反应发生率比较,差异无统计学意义(,P,>,0.05)。,结论,2,加用加味五虎追风散能更显著改善肾虚血瘀型帕金森病患者的抑郁、失眠、认知功能障碍等非运动症状,提升血清APN、UA水平,且安全性良好。
Objective,2,To observe the clinical effect of modified Wuhu Zhuifeng Powder on non-motor symptoms of Parkinson’s disease (PD) patients with kidney deficiency and blood stasis syndrome.,Methods,2,Eighty-four PD cases of kidney deficiency and blood stasis syndrome were randomly divided into control group (,n,=42) and treatment group (,n,=42). The control group was administered with levodopa and benserazide hydrochloride tablets, while the treatment group was additionally administered with modified Wuhu Zhuifeng Powder besides the basic treatment of the control group. The course of treatment in both groups was 3 months. The clinical effect and medication safety were observed, and the changes of scores of Non-motor Symptom Quest (NMS-Quest), Hamilton Depression Scale (HAMD), Parkinson’s Disease Sleep Scale (PDSS), and Mini-Mental State Examination (MMSE), as well as the changes of serum adiponectin (APN) and uric acid (UA) levels were compared.,Results,2,①During the trial, there was no drop-out case in both groups, and 84 cases finally completed the trial. ②The total effective rates of the treatment group and the control group were 83.33% and 26.19% respectively; The difference in the clinical effect between two groups was statistically significant (,P,<,0.05). ③The scores of NMS-Quest and HAMD in the two groups were significantly different before and after treatment (,P,<,0.05), and the scores in the treatment group decreased significantly and those in the control group increased significantly. After treatment, the scores of NMS-Quest and HAMD in the treatment group were significantly lower than those in the control group (,P,<,0.05). ④There were significant differences in PDSS and MMSE scores in the treatment group before and after treatment (,P,<,0.05), while there was no significant difference in the control group before and after treatment (,P,>,0.05). After treatment, the scores of PDSS and MMSE in the treatment group were significantly higher than those in the control group (,P,<,0.05). ⑤There were significant differences in APN and UA levels in the treatment group before and after treatment (,P,<,0.05), while there was no significant difference in the control group before and after treatment (,P,>,0.05). After treatment, the levels of APN and UA in the treatment group were significantly higher than those in the control group (,P,<,0.05). ⑥There was no significant difference in the incidence of adverse reactions between the two groups (,P,>,0.05).,Conclusion,2,Combined use of modified Wuhu Zhuifeng Powder can significantly relieve non-motor symptoms such as depression, insomnia, cognitive dysfunction in patients with Parkinson’s disease of kidney deficiency and blood stasis syndrome, and up-regulate the serum levels of APN and UA with satisfactory medication safety.
帕金森病肾虚血瘀证中医药疗法加味五虎追风散非运动症状抑郁
Parkinson’s diseasekidney deficiency and blood stasis syndrometraditional Chinese medicine therapymodified Wuhu Zhuifeng Powdernon-motor symptomdepression
SONG W, GUO X, CHEN K, et al. The impact of non-motor symptoms on the Health-Related Quality of Life of Parkinson’s disease patients from south west China [J]. Parkinsonism Relat disord, 2014, 20(2): 149-152.
陈畅,梁艳,唐莉莉,等. 温肾养肝方治疗帕金森病非运动症状30例临床研究[J]. 时珍国医国药,2017, 28(3): 130-132.
张兴博,梁健芬,郭旭堂. 加味五虎追风散治疗帕金森病疗效观察[J]. 中西医结合心脑血管病杂志,2015, 13(7): 934-936.
黄少东,梁健芬,张兴博,等. 加味五虎追风散对帕金森病患者血清IL-1β、Cys-C、Hcy水平及运动症状影响的临床研究[J]. 上海中医药杂志,2019, 53(5): 60-63.
中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志,2016, 49(4): 268-271.
中华全国中医学会老年医学会. 中医老年颤证诊断及疗效评定标准[J]. 北京中医学院学报,1992, 15(4): 39-41.
POSTUMA R B, BERG D, STERN M, et al. MDS clinical diagnostic criteria for Parkinson’s disease[J]. Mov Disord, 2015, 30(12): 1591-1601.
中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第三版)[J]. 药学与临床研究,2014, 43(6): 428-433.
国家药品监督管理局. 中药新药临床研究指导原则[M]. 北京:中国医药科技出版社,2002: 90.
SANTIAGO P L, MALCO R, MARCELO M, et al. Nonmotor symptoms groups in Parkinson’s disease patients: results of a pilot, exploratory study[J]. Parkinsons Dis, 2011, 35(4): 35-79.
张明园. 精神科评定量表手册[M]. 长沙:湖南科学技术出版社,2003:121.
ARIAS P, VIVAS J, GRIEVE K L, et al. Double-blind randomized place controlled trial on the effect of 10 days low-frequency rTMS over the vertex on sleep in Parkinson’s disease[J]. Sleep Med, 2010, 11 (8): 759-765.
PONT-SUNYER C, HOTTER A, GAIG C, et al. The Onset of Nonmotor Symptoms in Parkinson’s disease (The ONSET PD Study)[J]. Mov Disord, 2015, 30(2): 229-237.
KIM S R,SO H Y,CHOI E,et al. Influencing effect of non-motor symptom clusters on quality of life in Parkinson’s disease[J]. J Neurol Sci,2014,347(1-2): 310-315.
SEPPI K, WEINTRAUB D, COELHO M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s Disease[J]. Mov Disord, 2011, 26(Suppl 3): S42-S80.
韩世友. “控帕汤”联合美多巴治疗气血亏虚型帕金森病的临床研究[J]. 中华中医药学刊,2014, 32(1): 161-163.
TOMASIUK R, SZLUFIK S, FRIEDMAN A, et al. Ropinirole treatment in Parkinson’s disease associated with higher serum level of inflammatory biomarker NT-proCNP[J]. Neurosci Lett, 2014, 566 (5): 147-150.
KAMIGAKI M, SAKAUE S, TSUJINO I, et al. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes[J]. Biochem Biophys Res Commun, 2006, 339(2): 624-632.
杨新新,李中军,张沈阳,等. 帕金森病患者血清脂联素水平与运动症状及非运动症状的相关性[J]. 神经疾病与精神卫生,2015, 15(1): 9-11.
胡霞,陈方方,孔陈苏. 脂联素对帕金森病模型大鼠免疫炎症及氧化应激的保护作用[J]. 中国老年学杂志,2016, 36(15): 3662-3664.
徐周. 尿酸对帕金森保护作用的研究进展[D]. 苏州:苏州大学,2014.
JESUS S, PEREZ I, CACERES-REDONDO M T, et al. Low serum uric acid concentration in Parkinson’s disease in Southern Spain[J]. Eur J Neurol, 2012, 20(1): 208-210.
MOCCIA M, PICILLO M, ERRO R, et al. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson’s disease[J]. Eur J Neurol, 2015, 22(1): 93-98.
0
浏览量
276
下载量
0
CSCD
10
CNKI被引量
关联资源
相关文章
相关作者
相关机构